Alzheimer's disease (AD), a progressive neurodegenerative disorder, demands early detection to mitigate irreversible cognitive decline. Structural magnetic resonance imaging (MRI) serves as a critical diagnostic tool, capturing 3D brain volumes to identify atrophy in the hippocampus, cortex, and ventricles-key biomarkers of AD. Traditional methods relying on manual MRI interpretation or invasive biomarkers like CSF analysis lack sensitivity and scalability for early-stage diagnosis. Recent advancements in artificial intelligence (AI), particularly 3D convolutional neural networks (CNNs) and vision transformers (ViTs), automate AD detection by extracting subtle pathological patterns from MRI data. Hybrid models integrating CNNs with attention mechanisms achieve over 95% accuracy in classifying AD, mild cognitive impairment (MCI), and cognitively normal subjects, while unsupervised frameworks address data scarcity through anomaly detection. However, challenges such as patient-level data leakage, computational complexity, and ethical concerns around AI interpretability persist. Future research must prioritize multimodal integration (e.g., genetic, cognitive, and gait data), lightweight architectures for clinical deployment, and rigorous validation across diverse cohorts. This review synthesizes advancements in AI-driven MRI analysis, underscoring its potential to transform AD diagnostics into a precise, accessible, and patient-centric framework.